ClinicalTrials.gov
public full text
Public Domain
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Glutathione is an important nutrient for brain function and loss of glutathione has been implicated in Parkinson's disease. Glutathione is an antioxidant made in the body out of three amino acids, the nutrients that make up protein. This study will determine whether administration of either dose of glutathione, as a nasal spray, improves PD symptoms over time in a population of individuals with Parkinson's disease (PD).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Targeted Amino Acid Supplement for People With Parkinson's Disease#803142
- A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects#867946
- Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease#969595
- An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease#1137672
- Cognitive Training in Parkinson's Disease, the iPARK Study#968553
Record · ID 856425
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive